DK0673258T3 - Polymerbundne camptothecinderivater - Google Patents
Polymerbundne camptothecinderivaterInfo
- Publication number
- DK0673258T3 DK0673258T3 DK94928387T DK94928387T DK0673258T3 DK 0673258 T3 DK0673258 T3 DK 0673258T3 DK 94928387 T DK94928387 T DK 94928387T DK 94928387 T DK94928387 T DK 94928387T DK 0673258 T3 DK0673258 T3 DK 0673258T3
- Authority
- DK
- Denmark
- Prior art keywords
- pct
- formula
- camptothecin
- units represented
- hydroxy
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 4
- 229920000642 polymer Polymers 0.000 title 1
- 229940127093 camptothecin Drugs 0.000 abstract 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000006850 spacer group Chemical group 0.000 abstract 2
- BOURDYMMTZXVRY-UHFFFAOYSA-N 2-(2-methylprop-2-enoylamino)acetic acid Chemical compound CC(=C)C(=O)NCC(O)=O BOURDYMMTZXVRY-UHFFFAOYSA-N 0.000 abstract 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical group CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 abstract 1
- VZKBEZDJWDUUFH-UHFFFAOYSA-N n-[2-(2-hydroxypropylamino)-2-oxoethyl]-2-methylprop-2-enamide Chemical group CC(O)CNC(=O)CNC(=O)C(C)=C VZKBEZDJWDUUFH-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939320781A GB9320781D0 (en) | 1993-10-08 | 1993-10-08 | Polymer-bound camptothecin derivatives |
| PCT/EP1994/003154 WO1995010304A1 (en) | 1993-10-08 | 1994-09-21 | Polymer-bound camptothecin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0673258T3 true DK0673258T3 (da) | 2003-08-25 |
Family
ID=10743226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94928387T DK0673258T3 (da) | 1993-10-08 | 1994-09-21 | Polymerbundne camptothecinderivater |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5773522A (enExample) |
| EP (1) | EP0673258B1 (enExample) |
| JP (1) | JPH08504217A (enExample) |
| KR (1) | KR100359005B1 (enExample) |
| CN (1) | CN1138565C (enExample) |
| AT (1) | ATE239507T1 (enExample) |
| AU (1) | AU679788B2 (enExample) |
| CA (1) | CA2150132A1 (enExample) |
| DE (1) | DE69432627T2 (enExample) |
| DK (1) | DK0673258T3 (enExample) |
| ES (1) | ES2198421T3 (enExample) |
| FI (1) | FI952746A7 (enExample) |
| GB (1) | GB9320781D0 (enExample) |
| HU (1) | HU215588B (enExample) |
| IL (1) | IL111173A (enExample) |
| MY (1) | MY116624A (enExample) |
| NZ (1) | NZ273952A (enExample) |
| PL (1) | PL178132B1 (enExample) |
| PT (1) | PT673258E (enExample) |
| RU (1) | RU2149646C1 (enExample) |
| TW (1) | TW316905B (enExample) |
| UA (1) | UA42706C2 (enExample) |
| WO (1) | WO1995010304A1 (enExample) |
| ZA (1) | ZA947823B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5646159A (en) * | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
| DE19512484A1 (de) | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| CA2267328A1 (en) * | 1996-09-30 | 1998-04-09 | Bayer Aktiengesellschaft | Glycoconjugates from modified camptothecin derivates (20-o-linkage) |
| DE19640969A1 (de) * | 1996-10-04 | 1998-04-16 | Bayer Ag | 20-0-verknüpfte Glycokonjugate von Camptothecin |
| ID23424A (id) | 1997-05-14 | 2000-04-20 | Bayer Ag | Glikokonjugat dari 20(s)-kamptotesin |
| GB9721070D0 (en) * | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Bioactive derivatives of camptothecin |
| GB9721069D0 (en) * | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| GB9915180D0 (en) * | 1999-06-29 | 1999-09-01 | Pharmacia & Upjohn Spa | Antitumour compound |
| AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
| AU1820400A (en) * | 1999-11-17 | 2001-05-30 | School Of Pharmacy, University Of London, The | Conjugates of hpma copolymer and ellipticin |
| US20020077290A1 (en) * | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
| GB0008928D0 (en) * | 2000-04-11 | 2000-05-31 | Pharmacia & Upjohn Spa | A method of administering an antitumour compound |
| US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
| US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| WO2003033525A1 (en) * | 2001-10-12 | 2003-04-24 | Debio Recherche Pharmacuetique S.A. | Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
| WO2003101998A1 (en) | 2002-06-03 | 2003-12-11 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
| ITPD20050242A1 (it) * | 2005-08-03 | 2007-02-04 | Fidia Farmaceutici | Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico |
| US7875602B2 (en) | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
| CN101265331B (zh) * | 2007-03-12 | 2010-10-13 | 中国科学院化学研究所 | Peg改性phpma材料及其制备方法 |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| WO2011150022A2 (en) | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| CA2908993C (en) * | 2013-04-10 | 2023-05-23 | Syndevrx, Inc. | Metap2 inhibitors and methods of treating obesity |
| EP3040393B1 (en) | 2013-08-26 | 2020-09-30 | Japan Science and Technology Agency | Adhesive |
| ES2893749T3 (es) | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| CA3239447A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| JP2022512826A (ja) | 2018-10-26 | 2022-02-07 | シンデブルックス，インコーポレイティド | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| US5258453A (en) * | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| GB9309663D0 (en) * | 1993-05-11 | 1993-06-23 | Erba Carlo Spa | Biologically active compounds |
-
1993
- 1993-10-08 GB GB939320781A patent/GB9320781D0/en active Pending
-
1994
- 1994-09-21 CA CA002150132A patent/CA2150132A1/en not_active Abandoned
- 1994-09-21 PL PL94309328A patent/PL178132B1/pl not_active IP Right Cessation
- 1994-09-21 HU HU9502084A patent/HU215588B/hu not_active IP Right Cessation
- 1994-09-21 NZ NZ273952A patent/NZ273952A/en unknown
- 1994-09-21 RU RU95112841A patent/RU2149646C1/ru not_active IP Right Cessation
- 1994-09-21 CN CNB941907759A patent/CN1138565C/zh not_active Expired - Fee Related
- 1994-09-21 JP JP7511221A patent/JPH08504217A/ja active Pending
- 1994-09-21 FI FI952746A patent/FI952746A7/fi unknown
- 1994-09-21 DK DK94928387T patent/DK0673258T3/da active
- 1994-09-21 EP EP94928387A patent/EP0673258B1/en not_active Expired - Lifetime
- 1994-09-21 WO PCT/EP1994/003154 patent/WO1995010304A1/en not_active Ceased
- 1994-09-21 ES ES94928387T patent/ES2198421T3/es not_active Expired - Lifetime
- 1994-09-21 US US08/448,330 patent/US5773522A/en not_active Expired - Fee Related
- 1994-09-21 DE DE69432627T patent/DE69432627T2/de not_active Expired - Fee Related
- 1994-09-21 UA UA95073111A patent/UA42706C2/uk unknown
- 1994-09-21 KR KR1019950702308A patent/KR100359005B1/ko not_active Expired - Fee Related
- 1994-09-21 AU AU77836/94A patent/AU679788B2/en not_active Ceased
- 1994-09-21 AT AT94928387T patent/ATE239507T1/de not_active IP Right Cessation
- 1994-09-21 PT PT94928387T patent/PT673258E/pt unknown
- 1994-09-22 TW TW083108713A patent/TW316905B/zh active
- 1994-10-05 IL IL11117394A patent/IL111173A/en not_active IP Right Cessation
- 1994-10-06 ZA ZA947823A patent/ZA947823B/xx unknown
- 1994-10-06 MY MYPI94002652A patent/MY116624A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ273952A (en) | 1996-10-28 |
| DE69432627T2 (de) | 2004-03-25 |
| RU2149646C1 (ru) | 2000-05-27 |
| HU215588B (hu) | 1999-01-28 |
| US5773522A (en) | 1998-06-30 |
| ATE239507T1 (de) | 2003-05-15 |
| HU9502084D0 (en) | 1995-09-28 |
| AU7783694A (en) | 1995-05-04 |
| PL309328A1 (en) | 1995-10-02 |
| PT673258E (pt) | 2003-09-30 |
| ZA947823B (en) | 1995-07-03 |
| MY116624A (en) | 2004-03-31 |
| KR100359005B1 (ko) | 2003-04-26 |
| EP0673258A1 (en) | 1995-09-27 |
| IL111173A (en) | 1998-10-30 |
| CA2150132A1 (en) | 1995-04-20 |
| AU679788B2 (en) | 1997-07-10 |
| PL178132B1 (pl) | 2000-03-31 |
| RU95112841A (ru) | 1997-06-27 |
| ES2198421T3 (es) | 2004-02-01 |
| FI952746A0 (fi) | 1995-06-05 |
| TW316905B (enExample) | 1997-10-01 |
| GB9320781D0 (en) | 1993-12-01 |
| JPH08504217A (ja) | 1996-05-07 |
| UA42706C2 (uk) | 2001-11-15 |
| FI952746A7 (fi) | 1995-06-05 |
| CN1138565C (zh) | 2004-02-18 |
| IL111173A0 (en) | 1994-12-29 |
| DE69432627D1 (en) | 2003-06-12 |
| EP0673258B1 (en) | 2003-05-07 |
| HUT71678A (en) | 1996-01-29 |
| CN1115564A (zh) | 1996-01-24 |
| WO1995010304A1 (en) | 1995-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0673258T3 (da) | Polymerbundne camptothecinderivater | |
| BR9408246A (pt) | Composto derivado de 3-azabicicloalcano N-substituído | |
| MX9408969A (es) | Composisciones farmaceuticas que comprenden microparticulas biodegradables y biocompatibles para el tratamiento de transtornos psicoticos, su uso y procedimiento para prepararlas. | |
| BG100951A (en) | Novel erythromycin derivatives, method for their preparation and their use as drugs | |
| TW283716B (enExample) | ||
| DE69021176D1 (de) | Polypeptid und Verfahren zu dessen Herstellung. | |
| MY109669A (en) | N,o-sulphated heparosans, process for, preparing them and pharmaceutical compositions containing them | |
| BG103673A (en) | 3'-n-oxide, 3'-n-dimethylamine, 9-oxime derivatives of erythromycin a | |
| DK0819132T3 (da) | Fremgangsmåde til fremstilling af anthracyclin-antibiotika | |
| EP0450420A3 (en) | Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments | |
| MD1788F2 (en) | Erythromycin A 9-O-oximes derivatives, pharmaceutical composition on base thereof and method of treatment of infectious diseases | |
| TW268015B (enExample) | ||
| IL125926A0 (en) | Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof | |
| AU6257394A (en) | New derivatives of glutamic and aspartic acids, a method of preparing them, and their use as drugs for enhancing memory and learning | |
| PH24709A (en) | Allylmercaptoacetylsydnonimines and pharmaceutical compositions thereof | |
| TW259787B (enExample) | ||
| TW327170B (en) | Aza-anthracyclinone derivatives | |
| IL114499A0 (en) | Pyrido (3,2,1-i,j)(3,1) benzoxazine derivatives pharmaceutical compositions containing them and their use | |
| DK0874863T3 (da) | 3-deoxy-3-descladinose-derivater fra erythromycin A og B | |
| HUP9802072A2 (hu) | Benzo-tiopiráno-indazol-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| ES476077A1 (es) | Un procedimiento para preparar derivados del acido 1,3-tia- zol-glioxilico. | |
| MY131175A (en) | Heterocyclic compounds |